AccessibilityHelpAbout Us
Cspc Pharmaceutical Group logo

Cspc Pharmaceutical Group(SEHK) 1093

Market CapHK$104.85BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1994)+4,798%
5 Year-11%
1 Year-20%
1 Month+1%
HK$8.77
-3.63%
-0.33Today
Cspc Pharmaceutical Group last closing stock price
MetricPriceDate
Last closeHKD 8.762026-09-10
Cspc Pharmaceutical Group stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-8.9%HKD 9.612026-09-03
1 month+0.63%HKD 8.702026-08-11
3 month+20.93%HKD 7.242026-06-12
Year to date+3.86%HKD 8.432025-12-31
1 year-19.97%HKD 10.942025-09-10
3 year+51.73%HKD 5.772023-09-11
5 year-10.57%HKD 9.792021-09-10
Since inception+4,798.01%HKD 0.191994-06-27

Cspc Pharmaceutical Group Financials at a Glance

Market Cap

HK$104.85BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥56.84B

Net Income (TTM)

CN¥11.15B

EPS (TTM)

HK$0.74

P/E Ratio

12.35

Dividend

HK$0.29

Beta (Volatility)

0.12 (Low)

Price

HK$8.77

Volume

150,126,516

Open

HK$8.90

Previous Close

HK$9.10

Daily Range

HK$8.71 - HK$9.09

52-Week Range

HK$6.53 - HK$10.96

Estimated Earnings Date

Mar 24, 2027

1093 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cspc Pharmaceutical Group

CSPC Pharmaceutical Group Limited is a leading pharmaceutical company focused on the development, production, and distribution of a wide range of pharmaceutical products. With a strong presence in China and expanding operations across Asia, the Americas, and Europe, CSPC is well-positioned to capitalize on the growing global healthcare market.

Products and Services
  • Finished drugs for various medical conditions, including oncology and neurological disorders
  • Active pharmaceutical ingredients (APIs) such as antibiotics and vitamins
  • Functional foods and healthcare services to enhance overall well-being
Growth Outlook
  • Revenue of CNY 18.34 billion in Q2 2026, reflecting strong demand for pharmaceutical products
  • Net income margin of 32.77% in Q2 2026, indicating effective cost management
  • Consistent investment in R&D, with CNY 2.99 billion allocated in Q2 2026 to drive innovation
Financial Highlights
  • Trailing twelve months (TTM) revenue of CNY 66.5 billion, showcasing robust growth
  • Net profit margin of 23.73% TTM, demonstrating strong profitability
  • Dividend yield of 3.31% TTM, providing attractive returns to shareholders
CSPC Pharmaceutical Group Limited operates in a highly competitive industry, yet it has established a solid reputation for quality and innovation. The company's diverse product portfolio addresses a wide range of health issues, from oncology to cardiovascular health, positioning it as a key player in the pharmaceutical sector. The recent financial performance highlights CSPC's ability to generate substantial revenue and maintain strong profit margins, which may appeal to potential investors. With ongoing investments in research and development, CSPC is poised for continued growth and expansion in the global market.
AI Generated • Aug 28, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

19,700

CEO

Lei Cai, PhD

Website

www.cspc.com.hk

Headquarters

Shijiazhuang, HE 050035, CN

1093 Financials

Key Financial Metrics (TTM)

Gross Margin

71.86%

Operating Margin

27.95%

Net Income Margin

23.73%

Return on Equity

20.68%

Return on Capital

11.43%

Return on Assets

13.07%

Earnings Yield

8.10%

Dividend Yield

3.19%

Payout Ratio

33.54%

Stock Overview

Market Cap

HK$104.85BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

11.52B

Volume

150.13M

Avg. Volume

101.58M

Financials (TTM)

Gross Profit

CN¥39.52B

Operating Income

CN¥12.84B

EBITDA

CN¥16.34B

Operating Cash Flow

CN¥9.29B

Capital Expenditure

-CN¥3.47B

Free Cash Flow

CN¥5.82B

Cash & ST Invst.

CN¥18.48B

Total Debt

CN¥652.37M

Cspc Pharmaceutical Group Performance Analysis

Cspc Pharmaceutical Group annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 35,975,851,1727.1%
20232023-12-31CNY 34,752,307,458-3.4%
20242024-12-31CNY 31,452,524,840-9.5%
20252025-12-31CNY 28,204,093,089-10.3%
Cspc Pharmaceutical Group sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-21.0%
Q22025-06-300.4%
Q42025-12-31-3.8%
Q22026-06-3046.5%
Cspc Pharmaceutical Group annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY 0.595.2%
20232023-12-31CNY 0.55-8.0%
20242024-12-31CNY 0.40-26.9%
20252025-12-31CNY 0.37-7.8%
Cspc Pharmaceutical Group sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-57.7%
Q22025-06-30100.0%
Q42025-12-31-45.5%
Q22026-06-30341.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CN¥18.34B

+11.7%

Gross Profit

CN¥13.97B

+18.9%

Gross Margin

76.15%

N/A

Market Cap

HK$104.85BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

HK$5.63M

N/A

Employees

18,626

N/A

Net Income

CN¥6.01B

+97.4%

EBITDA

CN¥7.90B

+74.0%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CN¥18.48B

+71.0%

Total Debt

CN¥652.37M

+67.8%

Accounts Receivable

CN¥8.47B

-28.9%

Inventory

CN¥2.96B

-14.3%

Long Term Debt

CN¥388.92M

+486.5%

Short Term Debt

CN¥263.45M

-18.3%

Return on Assets

13.07%

N/A

Return on Invested Capital

20.73%

N/A

Free Cash Flow

CN¥0.00

-100.0%

Operating Cash Flow

CN¥0.00

-100.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,641.17-0.00%
^DJIDJI
$52,463.84-0.01%
^IXICNASDAQ
$26,258.89-0.01%
BTCBitcoin
$78,596.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$150.74+0.02%
NVDANvidia
$218.80-0.02%
INTCIntel
$101.26-0.05%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$45.93+0.06%

Questions About 1093

What is the current price of Cspc Pharmaceutical Group?

Cspc Pharmaceutical Group is trading at HK$8.77 per share.

What is the 52-week range for Cspc Pharmaceutical Group?

Over the past 52 weeks, Cspc Pharmaceutical Group has traded between HK$6.53 and HK$10.96.

How much debt does Cspc Pharmaceutical Group have?

As of the most recent reporting period, Cspc Pharmaceutical Group reported total debt of CN¥714.08M.

How much cash does Cspc Pharmaceutical Group have on hand?

Cspc Pharmaceutical Group reported CN¥5.87B in cash and cash equivalents in its most recent financial results.

What is Cspc Pharmaceutical Group’s dividend yield?

Cspc Pharmaceutical Group currently has a dividend yield of 3.19%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services